{
    "title": "GSK lifts growth ambitions for HIV business on long-acting drug",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12571159/GSK-lifts-growth-ambitions-HIV-business-long-acting-drug.html",
    "date": "2023-09-28",
    "keywords": [
        "growth",
        "hiv",
        "business",
        "drug",
        "apretude",
        "burger",
        "gsk",
        "thursday",
        "viiv",
        "infection",
        "ceo",
        "version",
        "prevention",
        "reimbursement",
        "month",
        "mediumterm",
        "forecast",
        "pfizer",
        "shionogi",
        "element",
        "push",
        "group",
        "walmsley",
        "investor",
        "confidence",
        "strength",
        "development",
        "pipeline",
        "virus",
        "companys",
        "guidance",
        "july",
        "demand",
        "focus",
        "capital",
        "day",
        "percentage",
        "injection",
        "acceptance",
        "population",
        "brand",
        "cabenuva",
        "use",
        "longer",
        "antihiv",
        "treatment",
        "preexposure",
        "prophylaxis",
        "pill",
        "truvada",
        "teva",
        "atripla",
        "deborah",
        "approval",
        "europe",
        "countrybycountry",
        "situation",
        "perspective",
        "followup",
        "success",
        "one",
        "end",
        "decade",
        "company",
        "stepwise",
        "loss",
        "patent",
        "protection",
        "ingredient",
        "dolutegravir",
        "secondquarter",
        "anil",
        "dsilva"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}